VAKCINA

Erős Pista wrote:

Mór Thököly wrote:Dobro, ali...sta, zasto, kako, koja je veza?

Aha!!!

Sotir wrote:Ако је МНЕ у праву, имаћемо ускоро још 50 различитих сојева, за сваку земљу у којој је АЗ почео масовно да се користи. Укљ и српски. А можда се ови избосне извуку. 

Што значи да можемо бити безбедни од тога.

rumbeando wrote:Znači po tvojoj logici sad treba da očekujemo još više hiljada novih sojeva kad je vakcinacija postala masovna pošto je, je li, testiranje sa desetak hiljada ispitanika u tri zemlje od kojih pola nije primilo vakcinu već placebo, a od onih koji jesu pozitivnih na testiranju je bilo sveukupno 68, dalo čak tri soja.



https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2932661-1

And Bloomberg have also had the briefing from the EUhttps://t.co/HYNTtaeSVI

— Alex Wickham (@alexwickham) March 21, 2021

The Biden administration on Thursday revealed the outlines of a plan to “loan” a limited number of vaccines to Canada and Mexico as the president announced the U.S. is on the cusp of meeting his 100-day injection goal “way ahead of schedule.”

“I’m proud to announce that tomorrow, 58 days into our administration, we will have met our goal,” Biden said. He promised to unveil a new vaccination target next week, as the U.S. is on pace to have enough of the three currently authorized vaccines to cover the entire adult population just 10 weeks from now.

Ahead of Biden’s remarks, the White House said it was finalizing plans to send a combined 4 million doses of the AstraZeneca COVID-19 vaccine to Mexico and Canada in its first export of shots. Press secretary Jen Psaki said the details of the “loan” were still being worked out, but 2.5 million doses would go to Mexico and 1.5 million would be sent to Canada.

"Until this morning, nearly 4.5 crore Covid-19 vaccine doses have been given to the people in this country. More than six crore doses have been sent to 76 nations," Union Health Minister Harsh Vardhan said during a media interaction at the Institute of Microbial Technology.

Good Morning!

Fabulous news out of AstraZeneca

Report from US trial: regimen showed 79% efficacy against symptomatic disease

100% effective against hospitalizations, deaths

This really is important for the world

Why?

Threadhttps://t.co/Da2vzS3bbj

— Ashish K. Jha, MD, MPH (@ashishkjha) March 22, 2021

But here's what makes it so so important

This is the vaccine that will likely vaccinate the world

Why?

Most important, underappreciated part: its relatively easy to store and make

So if you were rooting for global vaccination, this is a good morning

Fin

— Ashish K. Jha, MD, MPH (@ashishkjha) March 22, 2021

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation.

This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had a 2:1 randomisation of vaccine to placebo.

Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%.

The vaccine was well tolerated, and the independent data safety monitoring board (DSMB) identified no safety concerns related to the vaccine. The DSMB conducted a specific review of thrombotic events, as well as cerebral venous sinus thrombosis (CVST) with the assistance of an independent neurologist. The DSMB found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial.
...
Amongst participants in the interim analysis, approximately 79% were white/Caucasian, 8% black/African American, 4% native American and 4% Asian, and 22% of participants were Hispanic.

Approximately 20% of participants were 65 years and over, and approximately 60% had co-morbidities associated with an increased risk for progression of severe COVID-19, such as diabetes, severe obesity or cardiac disease.

This AstraZeneca-led US Phase III trial included two doses administered at a four week interval.

Moderna tests new Covid-19 vaccine candidate in early-stage study https://t.co/ZYRcgKjPto

— ST Foreign Desk (@STForeignDesk) March 15, 2021

Another biased comment against safe and efficient Sputnik V by European Internal Market Commissioner Thierry Breton, the head of the EU Commission's special vaccine task force. Biases lead to failures. And Breton’s failures are clear to many people in EU.https://t.co/mAYCTYERvh

— Sputnik V (@sputnikvaccine) March 21, 2021

If this is an official position of the EU, please inform us that there is no reason to pursue EMA approval because of your political biases. We will continue to save lives in other countries.

— Sputnik V (@sputnikvaccine) March 21, 2021

In the last 7 days:
Virchow Biotech, 200 mln doses for 100 mln people
Stelis Biorharma, 200 mln doses for 100 mln people
Gland Pharma, 252 mln doses for 126 mln people

— Sputnik V (@sputnikvaccine) March 22, 2021